Allogeneic Car Development Programs News Today

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca

. Cellectis announced completion of the additional equity investment of $140M by AstraZeneca . Cash position of $143 million as of March 31

•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology 65th Annual Meeting •   Execution of strategic...

•  Strategic Collaboration and Investment Agreements signed with AstraZenecaUpdated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/...

First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s... | May 4, 2023

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r M...

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical stud...